Efficacy Study in Removing Excess Iron From the Heart
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00105495|
Recruitment Status : Completed
First Posted : March 16, 2005
Last Update Posted : January 5, 2016
|Condition or disease||Intervention/treatment||Phase|
|Thalassemia Major Hemosiderosis||Drug: Ferriprox (deferiprone) Drug: Desferal (deferoxamine)||Phase 4|
This study is a multi-center, randomized, open-label, controlled clinical trial. The study population is participants with thalassemia major who are receiving regular chelation therapy with deferoxamine. A total of sixty (60) participants will be enrolled among the investigative sites.
The primary objective of this study is to determine whether deferiprone exhibits superior efficacy in removing excess iron from the heart compared to that of the standard therapy, deferoxamine.
The secondary objective is to evaluate the relative efficacy of deferiprone with respect to that of deferoxamine as assessed by serum ferritin concentration and liver iron concentration.
The primary efficacy measure in this study will be the participants' cardiac iron status, as determined by heart MRI T2* assessments.
The secondary efficacy measure will be by serum ferritin concentration and liver iron concentration. This will be measured by the Superconducting Quantum-Interference Device (SQUID) BioSusceptometer.
The duration of treatment is 12 months.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Randomized Trial Comparing the Relative Efficacy of Deferiprone to That of Deferoxamine in Removing Excess Cardiac Iron in Thalassemia Major Patients|
|Study Start Date :||December 2002|
|Estimated Study Completion Date :||October 2004|
U.S. FDA Resources
- To determine whether deferiprone exhibits superior efficacy in removing excess iron from the heart compared to that of deferoxamine, as reflected by MRI T2* assessments in the heart in participants treated with either chelator
- To evaluate the relative efficacy of deferiprone with respect to that of deferoxamine as assessed by serum ferritin concentration and liver iron concentration (LIC)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00105495
|1st Department of Pediatrics, Athens University, Aghia Sophia Children's Hospital|
|Athens, Greece, 11527|
|Aghia Sophia Children's Hospital|
|Athens, Greece, 11527|
|Ospedale Regionale Microcitemie, Dipartimento di Scienze|
|Cagliari, Sardegna, Italy, 09100|
|Dipartimento di Scienze e Dell' Adolescenza, University of Turin|
|Turin, Italy, 10126|
|Principal Investigator:||Renzo Galanello, M.D.||Ospedale Regionale Microcitemie, Cagliari, Italy|
|Principal Investigator:||Antonio Piga, M.D.||Dipartimento di Scienze Pediatriche e Dell'Adolescenza, University of Turin, Turin, Italy|
|Principal Investigator:||Markissia Karagiorga, M.D.||Aghia Sophia Children's Hospital, Athens, Greece|
|Principal Investigator:||Vassilis Ladis, M.D.||1st Department of Pediatrics, Athens University, Aghia Sophia Children's Hospital, Athens, Greece|